INSMED Inc (INSM) Stock Analysis and Metrics

Insmed

NASDAQ: INSM

$106.92 ▼ -0.49 (-0.46%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap23.02 Bn

P/E-19.45

P/S28.09

Div. Yield0.00

ROIC (Qtr)-0.48

Total Debt (Qtr)546.77 Mn

Revenue Growth (1y) (Qtr)229.62

Add ratio to table…

About

INSMED Inc is a global biopharmaceutical company focused on discovering developing and commercializing therapies for patients with serious diseases. The company concentrates its efforts in three therapeutic areas: respiratory immunology and inflammation and neuro and other rare. Its approach combines internal research with in licensing and acquisition activities to build a portfolio of approved medicines and investigational candidates.

INSMED generates revenue primarily from the sale of its two approved products ARIKAYCE and BRINSUPRI. ARIKAYCE is an inhaled antibiotic used to treat nontuberculous mycobacterial lung disease caused by MAC. BRINSUPRI is an oral tablet indicated for non cystic fibrosis bronchiectasis. Revenue is derived from product sales to wholesalers distributors and specialty pharmacies in the United States Europe and Japan. The company also may receive milestone payments and royalties from licensing agreements but its core revenue stream comes from product sales.

The company operates through the following segments: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.

• The Respiratory segment includes the approved products ARIKAYCE for MAC lung disease and BRINSUPRI for bronchiectasis. It also contains pipeline candidates such as TPIP an inhaled dry powder formulation being studied for pulmonary hypertension associated with interstitial lung disease pulmonary arterial hypertension progressive pulmonary fibrosis and idiopathic pulmonary fibrosis and INS1148 a monoclonal antibody targeting a specific isoform of Stem Cell Factor.

• The Immunology & Inflammation segment focuses on the development of brensocatib a small molecule inhibitor of dipeptidyl peptidase 1 for the treatment of hidradenitis suppurativa and other inflammatory conditions.

• The Neuro & Other Rare segment consists of gene therapy programs including INS1201 an intrathecally delivered treatment for Duchenne muscular dystrophy and INS1202 an intrathecally delivered therapy aimed at patients with amyotrophic lateral sclerosis.

INSMED occupies a niche position in the biopharmaceutical industry by concentrating on rare and serious diseases where few approved therapies exist. Its competitive advantages include proprietary drug delivery technologies such as the Pulmovance liposomal platform for ARIKAYCE and novel mechanisms of action like the DPP1 inhibition of brensocatib. The company has secured orphan drug designations in multiple jurisdictions which provide periods of market exclusivity and reduce direct competition for its approved indications.

INSMED serves patients diagnosed with rare lung diseases immunologic disorders and neurologic conditions. Its customers include hospitals specialty clinics and healthcare providers who prescribe ARIKAYCE and BRINSUPRI to eligible patients. The company also works with wholesalers and specialty pharmacies that distribute its products in the United States Europe and Japan.

Investment Thesis

▲ Bull case

Insmed's BRINSUPRI launch is demonstrating exceptional momentum with a strong foundation for sustained growth that the market is underestimating, particularly through organic demand dynamics and expanding patient populations. Management noted that organic demand is growing steadily and will account for all new patient growth moving forward as the 'ready and waiting' cohort effect has ended, signaling a transition to self-sustaining growth driven by genuine market adoption rather than pent-up demand. The company has already achieved over 5,000 unique prescribers, representing more than 25% of U.S. pulmonologists at quarter-end, with significant depth opportunity remaining as approximately 1,800 physicians had prescribed BRINSUPRI to only one patient by end of December 2025, and half of those had prescribed it to at least one additional patient by Q1 2026, indicating broadening adoption beyond initial adopters. Furthermore, direct-to-patient and provider disease awareness campaigns, including the national initiative with Ty Pennington and collaboration with the American Thoracic Society's EHR-based diagnosis initiative, are accelerating to expand diagnosis of bronchiectasis in comorbid populations like COPD and asthma patients, which could substantially increase the addressable market beyond current estimates. The continuation rate tracking slightly above generic statin analogs (which achieve ~70% at six months) and prescription refill frequency of 'nearly every 30 days'—faster than the 37-day industry benchmark—suggest strong real-world patient satisfaction and adherence, reducing churn risk and supporting durable revenue growth. With $1.2 billion in cash, cash equivalents, and marketable securities at quarter-end and a clear path to sustainable cash flow positivity in 2027 without new capital, Insmed has ample financial flexibility to fund pipeline advancement and potential business development without dilution risk, reinforcing confidence in executing its long-term vision.
The ARIKAYCE label expansion opportunity represents a significant near-term catalyst that could transform the drug into a blockbuster with minimal incremental investment, a factor the market appears to be overlooking amid focus on BRINSUPRI's launch. Management disclosed that positive Phase IIIb ENCORE results showed statistically significant improvement in patient-reported respiratory symptom score and over 80% sputum culture conversion at six months in the early treatment group for newly diagnosed NTM MAC patients, directly supporting a label expansion from the current refractory population of approximately 30,000 patients to over 200,000 patients if regulatory submissions in the U.S. and Japan are successful—a potential increase of more than 560%. The company plans to submit these results to U.S. and Japanese regulators within the year, with potential approval supporting an expanded label in the first half of 2027 and creating a $1 billion-plus peak sales opportunity for ARIKAYCE, which would meaningfully diversify revenue streams and reduce reliance on BRINSUPRI alone. This expansion leverages ARIKAYCE's existing commercial infrastructure, including its established specialty pharmacy network and payer approval processes (nearly 90% approval rate since launch), minimizing additional commercialization costs while tapping into a vastly larger patient population. Crucially, ARIKAYCE achieved year-over-year growth in its eighth year after launch despite targeting only refractory NTM MAC patients, demonstrating underlying product resilience and physician loyalty that would amplify upon label expansion. The near-term nature of this catalyst—regulatory submission in H2 2026 and potential approval in H1 2027—combined with the magnitude of the addressable market increase, presents a high-probability, high-impact upside scenario not fully reflected in current valuations.
TPIP's Phase III progress contains underappreciated value drivers related to dosing flexibility and clinical trial enthusiasm that could accelerate development and enhance commercial prospects beyond current expectations. Management highlighted that about 25% of open-label extension (OLE) participants in the Phase IIb study achieved doses above 640 micrograms, with seven patients reaching the maximum studied dose of 1,280 micrograms, demonstrating both tolerability and real-world willingness to uptitrate—a critical factor given that all four planned Phase III trials (PALM PAH, PALM-ILD, PPF, IPF) are now open or nearing protocol finalization and will evaluate doses up to 1,280 micrograms. This organic dose escalation in the OLE, driven by physician and patient choice without company encouragement, suggests that higher doses may be both achievable and beneficial in real-world settings, potentially strengthening the efficacy profile for regulatory approval. Furthermore, the company noted enthusiasm for trial enrollment even in the U.S. despite competition from other marketed treprostinil products, with physicians choosing to enroll patients in the TPIP trial (including placebo arm) based on positive prior data, indicating strong investigator confidence in the molecule's potential. The ability to deliver continuous, once-daily dosing of much higher treprostinil doses directly to the lung positions TPIP as an optimization of existing treprostinil therapy, which could yield superior outcomes in fibrotic lung diseases like IPF and PPF where dose dependency is suspected. With data from the Phase IIb OLE in PAH expected in Q3 2026 and all four Phase III trials advancing, TPIP represents a multi-shot pipeline asset with de-risked dosing and strong clinical enthusiasm that could deliver meaningful near-term milestones and long-term value if successful across indications.

Insmed's BRINSUPRI launch is demonstrating exceptional momentum with a strong foundation for sustained growth that the market is underestimating, particularly through organic demand dynamics and expanding patient populations. Management noted that organic demand is growing steadily and will account for all new patient growth moving forward as the 'ready and waiting' cohort effect has ended, signaling a transition to self-sustaining growth driven by genuine market adoption rather than pent-up demand. The company has already achieved over 5,000 unique prescribers, representing more than 25% of U.S. pulmonologists at quarter-end, with significant depth opportunity remaining as approximately 1,800 physicians had prescribed BRINSUPRI to only one patient by end of December 2025, and half of those had prescribed it to at least one additional patient by Q1 2026, indicating broadening adoption beyond initial adopters. Furthermore, direct-to-patient and provider disease awareness campaigns, including the national initiative with Ty Pennington and collaboration with the American Thoracic Society's EHR-based diagnosis initiative, are accelerating to expand diagnosis of bronchiectasis in comorbid populations like COPD and asthma patients, which could substantially increase the addressable market beyond current estimates. The continuation rate tracking slightly above generic statin analogs (which achieve ~70% at six months) and prescription refill frequency of 'nearly every 30 days'—faster than the 37-day industry benchmark—suggest strong real-world patient satisfaction and adherence, reducing churn risk and supporting durable revenue growth. With $1.2 billion in cash, cash equivalents, and marketable securities at quarter-end and a clear path to sustainable cash flow positivity in 2027 without new capital, Insmed has ample financial flexibility to fund pipeline advancement and potential business development without dilution risk, reinforcing confidence in executing its long-term vision.
The ARIKAYCE label expansion opportunity represents a significant near-term catalyst that could transform the drug into a blockbuster with minimal incremental investment, a factor the market appears to be overlooking amid focus on BRINSUPRI's launch. Management disclosed that positive Phase IIIb ENCORE results showed statistically significant improvement in patient-reported respiratory symptom score and over 80% sputum culture conversion at six months in the early treatment group for newly diagnosed NTM MAC patients, directly supporting a label expansion from the current refractory population of approximately 30,000 patients to over 200,000 patients if regulatory submissions in the U.S. and Japan are successful—a potential increase of more than 560%. The company plans to submit these results to U.S. and Japanese regulators within the year, with potential approval supporting an expanded label in the first half of 2027 and creating a $1 billion-plus peak sales opportunity for ARIKAYCE, which would meaningfully diversify revenue streams and reduce reliance on BRINSUPRI alone. This expansion leverages ARIKAYCE's existing commercial infrastructure, including its established specialty pharmacy network and payer approval processes (nearly 90% approval rate since launch), minimizing additional commercialization costs while tapping into a vastly larger patient population. Crucially, ARIKAYCE achieved year-over-year growth in its eighth year after launch despite targeting only refractory NTM MAC patients, demonstrating underlying product resilience and physician loyalty that would amplify upon label expansion. The near-term nature of this catalyst—regulatory submission in H2 2026 and potential approval in H1 2027—combined with the magnitude of the addressable market increase, presents a high-probability, high-impact upside scenario not fully reflected in current valuations.
TPIP's Phase III progress contains underappreciated value drivers related to dosing flexibility and clinical trial enthusiasm that could accelerate development and enhance commercial prospects beyond current expectations. Management highlighted that about 25% of open-label extension (OLE) participants in the Phase IIb study achieved doses above 640 micrograms, with seven patients reaching the maximum studied dose of 1,280 micrograms, demonstrating both tolerability and real-world willingness to uptitrate—a critical factor given that all four planned Phase III trials (PALM PAH, PALM-ILD, PPF, IPF) are now open or nearing protocol finalization and will evaluate doses up to 1,280 micrograms. This organic dose escalation in the OLE, driven by physician and patient choice without company encouragement, suggests that higher doses may be both achievable and beneficial in real-world settings, potentially strengthening the efficacy profile for regulatory approval. Furthermore, the company noted enthusiasm for trial enrollment even in the U.S. despite competition from other marketed treprostinil products, with physicians choosing to enroll patients in the TPIP trial (including placebo arm) based on positive prior data, indicating strong investigator confidence in the molecule's potential. The ability to deliver continuous, once-daily dosing of much higher treprostinil doses directly to the lung positions TPIP as an optimization of existing treprostinil therapy, which could yield superior outcomes in fibrotic lung diseases like IPF and PPF where dose dependency is suspected. With data from the Phase IIb OLE in PAH expected in Q3 2026 and all four Phase III trials advancing, TPIP represents a multi-shot pipeline asset with de-risked dosing and strong clinical enthusiasm that could deliver meaningful near-term milestones and long-term value if successful across indications.

▼ Bear case

Insmed's reliance on BRINSUPRI to drive near-term revenue and cash flow positivity creates significant concentration risk, particularly as the launch faces potential headwinds from evolving payer dynamics and the inherent challenges of sustaining hypergrowth beyond initial adoption phases, which the market may be underestimating. Although management reported a nearly 90% payer approval rate through specialty pharmacies since launch—well above internal benchmarks—they explicitly acknowledged that such high approval rates 'typically trend down over time' as launches mature, introducing uncertainty about long-term reimbursement stability amid increasing scrutiny on specialty drug pricing. The company's strategy of focusing on patients with two or more exacerbations to secure favorable payer access may become less effective if payers implement stricter utilization management criteria or shift formularies amid inflation reduction act pressures, potentially constraining new patient growth despite strong organic demand trends. Furthermore, while BRINSUPRI's continuation rate tracks slightly above generic statin analogs (~70% at six months), this benchmark may overstate durability given statins' well-established safety profile and decades of real-world use; BRINSUPRI, as a novel mechanism with limited long-term safety data beyond Phase III trials, could face unexpected discontinuation drivers as real-world evidence accumulates, particularly if dermatologic or gingival adverse reactions (noted in the ASPEN trial) lead to persistent tolerability issues. The assumption that organic demand will seamlessly replace the 'ready and waiting' cohort also overlooks the difficulty of converting physician adoption into consistent, high-volume prescribing, as evidenced by the fact that over 1,800 physicians had prescribed BRINSUPRI to only one patient by end of 2025, and only half increased to multiple prescriptions by Q1 2026—a slow depth progression that may limit peak prescribing potential. With guidance of at least $1 billion in 2026 BRINSUPRI revenue representing a substantial portion of total company value, any shortfall in sustained adoption or payer pushback could disproportionately impact financial projections and delay the path to cash flow positivity in 2027.
The ARIKAYCE label expansion opportunity, while promising, carries substantial regulatory and commercial execution risks that could delay or diminish its impact, risks the market may be overlooking amid enthusiasm for the ENCORE data. Management's plan to submit Phase IIIb ENCORE results to U.S. and Japanese regulators within the year for potential label expansion to all MAC lung infection patients (increasing addressable market from ~30,000 to over 200,000) assumes regulatory approval is likely, yet the ENCORE study focused on newly diagnosed patients—a population with different risk-benefit considerations than the refractory population that supported the original accelerated approval—and regulators may require additional safety or efficacy data, particularly given ARIKAYCE's known risks of respiratory adverse reactions (e.g., bronchospasm in 28.7% vs 10.7% in control, hemoptysis in 17.9% vs 12.5%). Even if approved, capturing the expanded market hinges on shifting physician behavior from reserving ARIKAYCE for last-line use to earlier-line adoption, a transition that could be slow due to entrenched treatment paradigms, safety concerns, and the need for education on earlier intervention benefits, potentially delaying revenue realization beyond the anticipated H1 2027 timeline. Moreover, ARIKAYCE's year-over-year growth of 6% in Q1 2026 (driven by international strength offsetting U.S. decline) reflects modest momentum in its current niche, raising questions about whether the product can achieve the necessary uptake velocity in a vastly larger population without significant commercial reinvestment—contradicting management's implication of minimal incremental cost. The company's cash burn, while stated to be 'within the range of quarterly burn that we have seen over the past year,' remains substantial given the $163.6 million net loss in Q1 2026, and any delay in ARIKAYCE label expansion revenue would prolong reliance on BRINSUPRI alone to fund operations and pipeline, increasing financial strain.
TPIP's Phase III development, while progressing, faces significant clinical and competitive risks that could undermine its value proposition, particularly as newer inhaled treprostinil formulations advance and trial results may not translate to meaningful differentiation in crowded pulmonary hypertension markets. Although management highlighted encouraging OLE data showing dose titration up to 1,280 micrograms and expressed enthusiasm for U.S. trial enrollment despite competing therapies, the absence of a placebo group in the OLE limits conclusions about dose-response efficacy, and the Phase III trials (PALM PAH, PALM-ILD, PPF, IPF) must demonstrate statistically significant superiority over existing approved treprostinil products (e.g., Tyvaso, Orenitram) to secure approval—a high bar given that treprostinil's efficacy is already established and incremental benefits from palmitilation may be modest. The company's hope that TPIP could represent an 'optimization' of treprostinil via higher lung delivery assumes dose linearity and sustained local exposure translate to superior outcomes, yet fibrotic endpoints in PPF and IPF are notoriously difficult to move, and recent positive IPF data from another treprostinil product may raise the competitive bar before TPIP reads out. Furthermore, the PALM PAH study's potential status as the 'only registrational trial required' for approval hinges on FDA agreement, which is not guaranteed, and any requirement for additional studies would delay timelines and increase costs. With all four Phase III trials now open or nearing finalization, the company is spreading resources across multiple indications simultaneously, increasing the risk that none achieve decisive success; a failure in one major trial (e.g., PAH) could negatively impact perception across the entire platform, especially given the shared mechanism and overlapping investor expectations for a franchise-defining asset. The expectation of OLE data in Q3 2026 provides near-term clarity, but if results fail to show clear differentiation over existing inhaled or oral treprostinil therapies, TPIP's valuation contribution could be materially lower than implied by pipeline optimism.

Insmed's reliance on BRINSUPRI to drive near-term revenue and cash flow positivity creates significant concentration risk, particularly as the launch faces potential headwinds from evolving payer dynamics and the inherent challenges of sustaining hypergrowth beyond initial adoption phases, which the market may be underestimating. Although management reported a nearly 90% payer approval rate through specialty pharmacies since launch—well above internal benchmarks—they explicitly acknowledged that such high approval rates 'typically trend down over time' as launches mature, introducing uncertainty about long-term reimbursement stability amid increasing scrutiny on specialty drug pricing. The company's strategy of focusing on patients with two or more exacerbations to secure favorable payer access may become less effective if payers implement stricter utilization management criteria or shift formularies amid inflation reduction act pressures, potentially constraining new patient growth despite strong organic demand trends. Furthermore, while BRINSUPRI's continuation rate tracks slightly above generic statin analogs (~70% at six months), this benchmark may overstate durability given statins' well-established safety profile and decades of real-world use; BRINSUPRI, as a novel mechanism with limited long-term safety data beyond Phase III trials, could face unexpected discontinuation drivers as real-world evidence accumulates, particularly if dermatologic or gingival adverse reactions (noted in the ASPEN trial) lead to persistent tolerability issues. The assumption that organic demand will seamlessly replace the 'ready and waiting' cohort also overlooks the difficulty of converting physician adoption into consistent, high-volume prescribing, as evidenced by the fact that over 1,800 physicians had prescribed BRINSUPRI to only one patient by end of 2025, and only half increased to multiple prescriptions by Q1 2026—a slow depth progression that may limit peak prescribing potential. With guidance of at least $1 billion in 2026 BRINSUPRI revenue representing a substantial portion of total company value, any shortfall in sustained adoption or payer pushback could disproportionately impact financial projections and delay the path to cash flow positivity in 2027.
The ARIKAYCE label expansion opportunity, while promising, carries substantial regulatory and commercial execution risks that could delay or diminish its impact, risks the market may be overlooking amid enthusiasm for the ENCORE data. Management's plan to submit Phase IIIb ENCORE results to U.S. and Japanese regulators within the year for potential label expansion to all MAC lung infection patients (increasing addressable market from ~30,000 to over 200,000) assumes regulatory approval is likely, yet the ENCORE study focused on newly diagnosed patients—a population with different risk-benefit considerations than the refractory population that supported the original accelerated approval—and regulators may require additional safety or efficacy data, particularly given ARIKAYCE's known risks of respiratory adverse reactions (e.g., bronchospasm in 28.7% vs 10.7% in control, hemoptysis in 17.9% vs 12.5%). Even if approved, capturing the expanded market hinges on shifting physician behavior from reserving ARIKAYCE for last-line use to earlier-line adoption, a transition that could be slow due to entrenched treatment paradigms, safety concerns, and the need for education on earlier intervention benefits, potentially delaying revenue realization beyond the anticipated H1 2027 timeline. Moreover, ARIKAYCE's year-over-year growth of 6% in Q1 2026 (driven by international strength offsetting U.S. decline) reflects modest momentum in its current niche, raising questions about whether the product can achieve the necessary uptake velocity in a vastly larger population without significant commercial reinvestment—contradicting management's implication of minimal incremental cost. The company's cash burn, while stated to be 'within the range of quarterly burn that we have seen over the past year,' remains substantial given the $163.6 million net loss in Q1 2026, and any delay in ARIKAYCE label expansion revenue would prolong reliance on BRINSUPRI alone to fund operations and pipeline, increasing financial strain.
TPIP's Phase III development, while progressing, faces significant clinical and competitive risks that could undermine its value proposition, particularly as newer inhaled treprostinil formulations advance and trial results may not translate to meaningful differentiation in crowded pulmonary hypertension markets. Although management highlighted encouraging OLE data showing dose titration up to 1,280 micrograms and expressed enthusiasm for U.S. trial enrollment despite competing therapies, the absence of a placebo group in the OLE limits conclusions about dose-response efficacy, and the Phase III trials (PALM PAH, PALM-ILD, PPF, IPF) must demonstrate statistically significant superiority over existing approved treprostinil products (e.g., Tyvaso, Orenitram) to secure approval—a high bar given that treprostinil's efficacy is already established and incremental benefits from palmitilation may be modest. The company's hope that TPIP could represent an 'optimization' of treprostinil via higher lung delivery assumes dose linearity and sustained local exposure translate to superior outcomes, yet fibrotic endpoints in PPF and IPF are notoriously difficult to move, and recent positive IPF data from another treprostinil product may raise the competitive bar before TPIP reads out. Furthermore, the PALM PAH study's potential status as the 'only registrational trial required' for approval hinges on FDA agreement, which is not guaranteed, and any requirement for additional studies would delay timelines and increase costs. With all four Phase III trials now open or nearing finalization, the company is spreading resources across multiple indications simultaneously, increasing the risk that none achieve decisive success; a failure in one major trial (e.g., PAH) could negatively impact perception across the entire platform, especially given the shared mechanism and overlapping investor expectations for a franchise-defining asset. The expectation of OLE data in Q3 2026 provides near-term clarity, but if results fail to show clear differentiation over existing inhaled or oral treprostinil therapies, TPIP's valuation contribution could be materially lower than implied by pipeline optimism.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password